Endocrinology

Kabi International Growth Study (Phase 4 data collection) (IRB# 2000-021)

Status: Active

 

Investigators:

  • Peter A Lee, MD, Ph.D.

 

Description:

The development of recombinant DNA technology has brought about the large-scale availability of biosynthetic human growth hormone for treatment of pediatric growth disorders. Children receiving Genotropin therapy will be followed on a long-term basis to assess the long-term safety and growth response to this therapy. The collection of these data will be integrated into the international database.

 

 

Eligibility:

Inclusion criteria

  • Children being treated with Genotropin for a growth disorder.

Exclusion criteria

 

  • Subjects with closed epiphyses and those with active malignancies.

 

 

Additional Study Details:

What is expected of me and my child?

Collection of data will be done following scheduled clinic visits for routine endocrine care. Data will be entered via a secure web site.

 

 

 

Locations:

  • Hershey Medical Center outpatient clinics.

 

Contacts:

Cynthia Gordner, RN, BS

cgordner@hmc.psu.edu

717-531-5656

 

Categories:

  • Endocrinology